Loblaw Q2 2025 Earnings Jumped 56%, Largely Thanks To Accounting

Loblaw Companies (TSX: L) posted Q2 2025 revenue of $14.67 billion, up 5.2% YoY and 3.8% from the prior quarter.

On operations, same-store food sales rose 3.5%, barely ahead of internal food inflation of 3.3%. Hard discount banners drove the gains, while drug retail comps added 4.1%, but that included a 6.2% lift from high-margin specialty drugs that could prove cyclical. E-commerce advanced 17.5% but still represents a single-digit share of total revenue.

Operating income vaulted 42.7% YoY to $1.24 billion from $868 million, far outstripping the revenue trajectory. The jump was driven by a $106 million drop in amortization tied to the now-fully written off Shoppers Drug Mart intangibles, not by any material gross margin expansion, which stayed flat at 32.0%. This is also aided by the one-time $164 million class action lawsuit settlement charges last year.

Net earnings jumped 56% YoY to $714 million from $457 million, lifting diluted EPS by 60.1% to $2.37. Strip out the amortization benefit and other one-offs, however, and adjusted net income rose a comparatively tame 8.6% YoY to $721 million, with adjusted EPS at $2.40, an 11.6% jump. Management’s claim that “customers are increasingly rewarding us” rings hollow against that disparity.

Adjusted EBITDA climbed to $1.84 billion, but the margin edged up only 20 basis points YoY to 12.5% and remains razor-thin relative to US grocery peers. Interest expense increased 11.6% YoY to $212 million, neutralizing roughly one-sixth of the EBITDA gain.

Consolidated free cash flow swung to a positive $468 million after last quarter’s retail outflow of $264 million, aided by reduced capex and property sale proceeds. Yet net capital investments of $239 million still trailed the $445 million returned to shareholders.

The board approved a 4-for-1 stock split effective August 18, ostensibly to “keep shares accessible,” yet the timing conveniently masks the EPS optics of share-repurchase-fuelled growth. Management reaffirmed “high single-digit” adjusted EPS expansion for 2025, but the guide already bakes in a 53rd-week tailwind worth roughly 2%. Remove that and the outlook implies mid-single-digit growth.

Loblaw last traded at $217.51 on the TSX.


Information for this briefing was found via the sources and companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why This Gold Run Could Be Bigger | Roger Rosmus – Goliath Resources

Majors Don’t Want to Be Left Out of This Gold Run | Mike Bennett – Altamira Gold Corp

Gold Isn’t Slowing Down Anytime Soon!? | Terry Lynch – Power Metallic

Recommended

Sage Potash Outlines US$502 Million NPV For Flagship Sage Plains Project

Ontario MPP Removed From Caucus After Assault Charges

Related News

Loblaw Misses Revenue Estimates In Q3 2024 Despite Profit Boost

Retail giant Loblaw Companies (TSX: L) fell short of revenue expectations in the third quarter, posting...

Wednesday, November 13, 2024, 03:05:00 PM

Loblaw, George Weston Agree to Massive $500M Settlement Over Bread Price-Fixing Case

Loblaw Companies (TSX: L) and its parent company George Weston (TSX: WN) have agreed to a...

Thursday, July 25, 2024, 11:28:00 AM

Per Bank Made Bank: Loblaw CEO Made A Hefty $22 Million Amid Boycott Calls

Loblaw Companies (TSX: L) has faced scrutiny after it disclosed the hefty compensation package of...

Tuesday, April 2, 2024, 11:44:00 AM

Loblaw’s Report Sees Food Prices Soar Beyond Inflation

Loblaw Companies Ltd. (TSX: L) has published its January Food Inflation report, highlighting persistent challenges...

Tuesday, January 21, 2025, 10:07:00 AM

Avicanna To Purchase Assets of Medical Cannabis By Shoppers For $2.6 Million

Avicanna (TSX: AVCN) has confirmed it will be moving forward with the previously announced plan...

Monday, May 29, 2023, 09:31:34 AM